OMER - Omeros Corporation
| Previous Close | 20.92 |
| Open | 21.01 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 20.92 - 22.25 |
| 52 Week Range | 8.36 - 25.20 |
| Volume | 597,517 |
| Avg. Volume | 599,993 |
| Market Cap | 1.072B |
| Beta | 3.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.84 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.20 |
- ACCESSWIRE•11 days ago
Today's Research Reports on Trending Tickers: Omeros and Intrexon
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...
- Business Wire•11 days ago
Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference
Omeros Corporation , today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of OMER earnings conference call or presentation 9-Aug-18 8:30pm GMT
Q2 2018 Omeros Corp Earnings Call
- Zacks•11 days ago
Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of 9.09% and -5.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Omeros: 2Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had a loss of 70 cents. Losses, adjusted for non-recurring costs, were 60 cents per share. The results topped Wall Street expectations. The average ...
- Business Wire•11 days ago
Omeros Corporation Reports Second Quarter 2018 Financial Results
– Conference Call Today at 4:30 p.m. ET –
- Business Wire•18 days ago
Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
Omeros Corporation (OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. To access the live and subsequently archived webcast of the conference call, go to Omeros’ website at www.omeros.com and go to “Events” under the Investors section of the website.
- Business Wire•19 days ago
Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer
– Company Expands Leadership to Keep Pace with Advancing Pivotal Clinical Programs –
- Business Wire•26 days ago
Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire
-- With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation --
- Business Wire•27 days ago
Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Corporation (OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Three OMS721 Phase 3 clinical programs are progressing across hematopoietic stem cell transplant-associated thrombotic microangiopathy (TMA), immunoglobulin A (IgA) nephropathy, and atypical hemolytic uremic syndrome (aHUS).
- Business Wire•29 days ago
Omeros Corporation Initiates Sales of OMIDRIA® in Europe
-- Sales maintain the drug’s European marketing authorization --
- Business Wire•last month
Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
Omeros Corporation (OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s dopamine levels, widely recognized as central to both addictive and compulsive disorders. With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS527 is nicotine addiction.
- ACCESSWIRE•last month
Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
- Business Wire•2 months ago
Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
Omeros Corporation (OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents internationally directed to PDE7 inhibitors for the treatment of all addictions and compulsive disorders.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics — Future Expectations, Projections Moving into 2018
NEW YORK, June 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ABIOMED, ...
- ACCESSWIRE•2 months ago
Breakfast Technical Briefing on Omeros and Three Other Additional Biotech Stocks
Stock Research Monitor: NLNK, OHRP, and ONCS LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want a free Stock Review on OMER sign up now at www.wallstequities.com/registration . On Monday, benchmark ...
- ACCESSWIRE•3 months ago
Wired News – Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R)
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Omeros Corp. (NASDAQ: OMER), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OMER as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has reached a settlement agreement with Lupin Ltd and its subsidiary Lupin Pharmaceuticals, Inc. ("Lupin") to resolve the patent infringement lawsuit filed against Lupin. Omeros had filed the case against Lupin as it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for approval to market a generic version of Omeros' commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
- Business Wire•3 months ago
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
Omeros Corporation (OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Omeros’ commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
- Motley Fool•3 months ago
Why Omeros, Party City Holdco, and Overstock.com Slumped Today
Find out which of these stocks was pressured by cryptocurrency fluctuations.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Omeros Corp Earnings Call
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: Omeros and bluebird bio
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / U.S. markets were mixed on Friday, with the Dow Jones logging its 7th consecutive daily gain, the longest streak since 2017. Comments from President Trump on ...
- Motley Fool•3 months ago
Here's Why Omeros Corporation Stock Is Surging Today
Pipeline progress outlined during the company's first-quarter report lifted spirits.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...
- Associated Press•3 months ago
Omeros: 1Q Earnings Snapshot
The Seattle-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, came to 53 cents per share. The drug developer posted revenue of $1.6 million in the period. ...
